Author Identifier
Pauline Zaenker
https://orcid.org/0000-0002-0807-1968
Johnny Lo
https://orcid.org/0000-0003-1913-5354
Elin Gray
https://orcid.org/0000-0002-8613-3570
Mel Ziman
Document Type
Journal Article
Publication Title
Oncotarget
Publisher
Impact Journals LLC
School
School of Medical and Health Sciences / School of Science
RAS ID
27177
Funders
National Health and Medical Research Council
Grant Number
NHMRC Number: 1076172
Abstract
Melanoma is an aggressive form of skin cancer that is curable by surgical excision in the majority of cases, if detected at an early stage. To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. Here we aimed to identify antibodies to a panel of tumour associated antigens that can differentiate primary melanoma patients and healthy individuals. A total of 245 sera from primary melanoma patients and healthy volunteers were screened against a high-throughput microarray platform containing 1627 functional proteins. Following rigorous statistical analysis, we identified a combination of 10 autoantibody biomarkers that, as a panel, displays a sensitivity of 79%, specificity of 84% and an AUC of 0.828 for primary melanoma detection. This melanoma autoantibody signature may prove valuable for the development of a diagnostic blood test for routine population screening that, when used in conjunction with current melanoma diagnostic techniques, could improve the early diagnosis of this malignancy and ultimately decrease the mortality rate of patients.
DOI
10.18632/oncotarget.25669
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Comments
Zaenker, P., Lo, J., Pearce, R., Cantwell, P., Cowell, L., Lee, M., ... & Ziman, M. (2018). A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 9(55), 30539-30551. Available here.